These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 21177789

  • 1. Pegylated long-acting human growth hormone possesses a promising once-weekly treatment profile, and multiple dosing is well tolerated in adult patients with growth hormone deficiency.
    Søndergaard E, Klose M, Hansen M, Hansen BS, Andersen M, Feldt-Rasmussen U, Laursen T, Rasmussen MH, Christiansen JS.
    J Clin Endocrinol Metab; 2011 Mar; 96(3):681-8. PubMed ID: 21177789
    [Abstract] [Full Text] [Related]

  • 2. Pegylated long-acting human growth hormone is well-tolerated in healthy subjects and possesses a potential once-weekly pharmacokinetic and pharmacodynamic treatment profile.
    Rasmussen MH, Bysted BV, Anderson TW, Klitgaard T, Madsen J.
    J Clin Endocrinol Metab; 2010 Jul; 95(7):3411-7. PubMed ID: 20427496
    [Abstract] [Full Text] [Related]

  • 3. Long-acting pegylated human GH in children with GH deficiency: a single-dose, dose-escalation trial investigating safety, tolerability, pharmacokinetics and pharmacodynamics.
    de Schepper J, Rasmussen MH, Gucev Z, Eliakim A, Battelino T.
    Eur J Endocrinol; 2011 Sep; 165(3):401-9. PubMed ID: 21724838
    [Abstract] [Full Text] [Related]

  • 4. Multiple doses of pegylated long-acting growth hormone are well tolerated in healthy male volunteers and possess a potential once-weekly treatment profile.
    Rasmussen MH, Jensen L, Anderson TW, Klitgaard T, Madsen J.
    Clin Endocrinol (Oxf); 2010 Dec; 73(6):769-76. PubMed ID: 20718773
    [Abstract] [Full Text] [Related]

  • 5. A reversible albumin-binding growth hormone derivative is well tolerated and possesses a potential once-weekly treatment profile.
    Rasmussen MH, Olsen MW, Alifrangis L, Klim S, Suntum M.
    J Clin Endocrinol Metab; 2014 Oct; 99(10):E1819-29. PubMed ID: 25013997
    [Abstract] [Full Text] [Related]

  • 6. Comparative pharmacokinetics and pharmacodynamics of a PEGylated recombinant human growth hormone and daily recombinant human growth hormone in growth hormone-deficient children.
    Hou L, Chen ZH, Liu D, Cheng YG, Luo XP.
    Drug Des Devel Ther; 2016 Oct; 10():13-21. PubMed ID: 26719670
    [Abstract] [Full Text] [Related]

  • 7. Three weekly injections (TWI) of low-dose growth hormone (GH) restore low normal circulating IGF-I concentrations and reverse cardiac abnormalities associated with adult onset GH deficiency (GHD).
    Pincelli AI, Bragato R, Scacchi M, Branzi G, Osculati G, Viarengo R, Leonetti G, Cavagnini F.
    J Endocrinol Invest; 2003 May; 26(5):420-8. PubMed ID: 12906369
    [Abstract] [Full Text] [Related]

  • 8. Reversible Albumin-Binding GH Possesses a Potential Once-Weekly Treatment Profile in Adult Growth Hormone Deficiency.
    Rasmussen MH, Janukonyté J, Klose M, Marina D, Tanvig M, Nielsen LF, Höybye C, Andersen M, Feldt-Rasmussen U, Christiansen JS.
    J Clin Endocrinol Metab; 2016 Mar; 101(3):988-98. PubMed ID: 26727076
    [Abstract] [Full Text] [Related]

  • 9. Somapacitan, a once-weekly reversible albumin-binding GH derivative, in children with GH deficiency: A randomized dose-escalation trial.
    Battelino T, Rasmussen MH, De Schepper J, Zuckerman-Levin N, Gucev Z, Sävendahl L, NN8640-4042 Study Group.
    Clin Endocrinol (Oxf); 2017 Oct; 87(4):350-358. PubMed ID: 28656605
    [Abstract] [Full Text] [Related]

  • 10. Two years of replacement therapy in adults with growth hormone deficiency.
    Verhelst J, Abs R, Vandeweghe M, Mockel J, Legros JJ, Copinschi G, Mahler C, Velkeniers B, Vanhaelst L, Van Aelst A, De Rijdt D, Stevenaert A, Beckers A.
    Clin Endocrinol (Oxf); 1997 Oct; 47(4):485-94. PubMed ID: 9404448
    [Abstract] [Full Text] [Related]

  • 11. Recombinant growth hormone (GH) therapy in GH-deficient adults: a long-term controlled study on daily versus thrice weekly injections.
    Amato G, Mazziotti G, Di Somma C, Lalli E, De Felice G, Conte M, Rotondi M, Pietrosante M, Lombardi G, Bellastella A, Carella C, Colao A.
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3720-5. PubMed ID: 11061530
    [Abstract] [Full Text] [Related]

  • 12. MOD-4023, a long-acting carboxy-terminal peptide-modified human growth hormone: results of a Phase 2 study in growth hormone-deficient adults.
    Strasburger CJ, Vanuga P, Payer J, Pfeifer M, Popovic V, Bajnok L, Góth M, Olšovská V, Trejbalová L, Vadasz J, Fima E, Koren R, Amitzi L, Bidlingmaier M, Hershkovitz O, Hart G, Biller BMK.
    Eur J Endocrinol; 2017 Mar; 176(3):283-294. PubMed ID: 27932411
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetics and Pharmacodynamics of Once-Weekly Somapacitan in Children and Adults: Supporting Dosing Rationales with a Model-Based Analysis of Three Phase I Trials.
    Juul RV, Rasmussen MH, Agersø H, Overgaard RV.
    Clin Pharmacokinet; 2019 Jan; 58(1):63-75. PubMed ID: 29671202
    [Abstract] [Full Text] [Related]

  • 14. Lipoatrophy in GH deficient patients treated with a long-acting pegylated GH.
    Touraine P, D'Souza GA, Kourides I, Abs R, Barclay P, Xie R, Pico A, Torres-Vela E, Ekman B, GH Lipoatrophy Study Group.
    Eur J Endocrinol; 2009 Oct; 161(4):533-40. PubMed ID: 19654233
    [Abstract] [Full Text] [Related]

  • 15. The pharmacokinetic and pharmacodynamic properties and short-term outcome of a novel once-weekly PEGylated recombinant human growth hormone for children with growth hormone deficiency.
    Liang Y, Zhang C, Wei H, Du H, Zhang G, Yang Y, Zhang H, Gong H, Li P, Song F, Xu Z, He R, Zhou W, Zheng H, Sun L, Luo X.
    Front Endocrinol (Lausanne); 2022 Oct; 13():922304. PubMed ID: 36034448
    [Abstract] [Full Text] [Related]

  • 16. [Efficacy and safety of recombinant human growth hormone solution in children with growth hormone deficiency in China: a multicenter trial].
    Hou L, Luo XP, Du ML, Ma HM, Gong CX, Li YC, Shen SX, Zhao ZH, Liang L, Dong GP, Yan CY, Du HW.
    Zhonghua Er Ke Za Zhi; 2009 Jan; 47(1):48-52. PubMed ID: 19573383
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Population pharmacokinetic/pharmacodynamic analysis of PEG-rhGH enhances confidence in exploring dosing schemes with longer intervals.
    Cheng R, Zhao Q, Zhong G, Xu J, Zheng Z, Xi L, Zhang M, Ni J, Hu P, Luo F, Lu W.
    Eur J Pharm Sci; 2022 Dec 01; 179():106304. PubMed ID: 36209987
    [Abstract] [Full Text] [Related]

  • 19. A long-acting pegylated recombinant human growth hormone (Jintrolong® ) in healthy adult subjects: Two single-dose trials evaluating safety, tolerability and pharmacokinetics.
    Guan Y, He F, Wu J, Zhao L, Wang X, Huang L, Zeng G, Ren B, Chen J, Liao X, Ma Z, Chen X, Zhong G, Huang M, Zhao X.
    J Clin Pharm Ther; 2018 Oct 01; 43(5):640-646. PubMed ID: 29959799
    [Abstract] [Full Text] [Related]

  • 20. Long-Acting C-Terminal Peptide-Modified hGH (MOD-4023): Results of a Safety and Dose-Finding Study in GHD Children.
    Zelinska N, Iotova V, Skorodok J, Malievsky O, Peterkova V, Samsonova L, Rosenfeld RG, Zadik Z, Jaron-Mendelson M, Koren R, Amitzi L, Raduk D, Hershkovitz O, Hart G.
    J Clin Endocrinol Metab; 2017 May 01; 102(5):1578-1587. PubMed ID: 28323965
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.